Literature DB >> 9493491

Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria.

M Steiner1, M Korzekwa, J Lamont, A Wilkins.   

Abstract

Some women experience premenstrual mood symptoms that severely disrupt their lives and relationships. These women often require pharmacologic treatment. Selective serotonin reuptake inhibitors, particularly daily fluoxetine, have been proven superior to placebo in several randomized controlled trials. Twenty-four women with confirmed premenstrual dysphoric disorder (PMDD) and with a history of affective disorders or alcoholism were treated with fluoxetine 20 mg/day (continuous), and 24 women with PMDD and no psychiatric history were treated with fluoxetine 20 mg/day for 14 days premenstrually only (intermittent). Both groups received treatment for three menstrual cycles. Sixteen women (66.7%) in the continuous dosing group and 18 women (75.0%) in the intermittent group were classified as treatment responders. Intermittent dosing of fluoxetine seems to be effective and mostly free of side effects in women with PMDD and, therefore, may offer an attractive treatment option for a disorder that is itself intermittent.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9493491

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  15 in total

Review 1.  Current update of hormonal and psychotropic drug treatment of premenstrual dysphoric disorder.

Authors:  Ellen W Freeman
Journal:  Curr Psychiatry Rep       Date:  2002-12       Impact factor: 5.285

Review 2.  Premenstrual syndrome and premenstrual dysphoric disorder: guidelines for management.

Authors:  M Steiner
Journal:  J Psychiatry Neurosci       Date:  2000-11       Impact factor: 6.186

Review 3.  The role of central serotonergic dysfunction in the aetiology of premenstrual dysphoric disorder: therapeutic implications.

Authors:  B L Parry
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial.

Authors:  Kimberly A Yonkers; Susan G Kornstein; Ralitza Gueorguieva; Brian Merry; Kari Van Steenburgh; Margaret Altemus
Journal:  JAMA Psychiatry       Date:  2015-10       Impact factor: 21.596

Review 5.  Selective serotonin reuptake inhibitors for premenstrual syndrome.

Authors:  Jane Marjoribanks; Julie Brown; Patrick Michael Shaughn O'Brien; Katrina Wyatt
Journal:  Cochrane Database Syst Rev       Date:  2013-06-07

6.  A qualitative investigation of women's perceptions of premenstrual syndrome: implications for general practitioners.

Authors:  J Reilly; J Kremer
Journal:  Br J Gen Pract       Date:  1999-10       Impact factor: 5.386

Review 7.  Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder.

Authors:  Ellen W Freeman
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 8.  A reproductive subtype of depression: conceptualizing models and moving toward etiology.

Authors:  Jennifer L Payne; Jennifer Teitelbaum Palmer; Hadine Joffe
Journal:  Harv Rev Psychiatry       Date:  2009       Impact factor: 3.732

Review 9.  Update on research and treatment of premenstrual dysphoric disorder.

Authors:  Joanne Cunningham; Kimberly Ann Yonkers; Shaughn O'Brien; Elias Eriksson
Journal:  Harv Rev Psychiatry       Date:  2009       Impact factor: 3.732

10.  Premenstrual Dysphoric Disorder: Recognition and Treatment.

Authors:  Ellen W. Freeman; Steven J. Sondheimer
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.